 Stephen Dreskin
Concepts (467)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 26 | 2023 | 140 | 7.330 |
Why?
| | Immunoglobulin E | 41 | 2024 | 329 | 5.910 |
Why?
| | Allergens | 23 | 2023 | 381 | 5.290 |
Why?
| | Antigens, Plant | 22 | 2023 | 46 | 5.250 |
Why?
| | 2S Albumins, Plant | 19 | 2023 | 29 | 5.060 |
Why?
| | Arachis | 19 | 2023 | 108 | 4.400 |
Why?
| | Glycoproteins | 12 | 2016 | 337 | 2.830 |
Why?
| | Urticaria | 11 | 2018 | 37 | 2.590 |
Why?
| | Epitopes | 8 | 2023 | 466 | 1.800 |
Why?
| | Mast Cells | 13 | 2021 | 141 | 1.570 |
Why?
| | Omalizumab | 3 | 2024 | 50 | 1.550 |
Why?
| | Basophils | 14 | 2018 | 72 | 1.500 |
Why?
| | Desensitization, Immunologic | 3 | 2019 | 89 | 1.100 |
Why?
| | Food Hypersensitivity | 3 | 2020 | 173 | 0.890 |
Why?
| | Benzoquinones | 4 | 2007 | 47 | 0.830 |
Why?
| | Nuts | 2 | 2023 | 10 | 0.770 |
Why?
| | Anaphylaxis | 3 | 2018 | 98 | 0.710 |
Why?
| | Anti-Allergic Agents | 3 | 2018 | 45 | 0.710 |
Why?
| | Receptors, IgE | 11 | 2003 | 44 | 0.700 |
Why?
| | Plant Proteins | 6 | 2023 | 88 | 0.680 |
Why?
| | Seeds | 1 | 2020 | 84 | 0.680 |
Why?
| | Amino Acids | 1 | 2023 | 476 | 0.660 |
Why?
| | Peptide Library | 2 | 2017 | 83 | 0.660 |
Why?
| | Peptide Mapping | 1 | 2019 | 61 | 0.650 |
Why?
| | Allergists | 1 | 2018 | 12 | 0.610 |
Why?
| | Protein Conformation | 5 | 2022 | 853 | 0.600 |
Why?
| | Allergy and Immunology | 1 | 2018 | 43 | 0.580 |
Why?
| | Immunoglobulin G | 7 | 2022 | 842 | 0.560 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2008 | 31 | 0.550 |
Why?
| | Plant Extracts | 3 | 2018 | 185 | 0.550 |
Why?
| | Bortezomib | 1 | 2016 | 45 | 0.530 |
Why?
| | Anti-Inflammatory Agents | 4 | 2008 | 467 | 0.520 |
Why?
| | Drug Hypersensitivity | 2 | 2013 | 81 | 0.510 |
Why?
| | Amino Acid Sequence | 7 | 2023 | 2042 | 0.490 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2014 | 57 | 0.490 |
Why?
| | Interleukin-5 | 2 | 2008 | 45 | 0.490 |
Why?
| | Hypersensitivity, Immediate | 4 | 2013 | 43 | 0.480 |
Why?
| | Humans | 71 | 2024 | 128019 | 0.450 |
Why?
| | Models, Molecular | 2 | 2016 | 1482 | 0.440 |
Why?
| | Peptides | 6 | 2023 | 910 | 0.440 |
Why?
| | Proteome | 1 | 2018 | 430 | 0.440 |
Why?
| | Animals | 33 | 2022 | 34487 | 0.430 |
Why?
| | Cell Degranulation | 3 | 2014 | 42 | 0.420 |
Why?
| | Cross Reactions | 4 | 2023 | 129 | 0.400 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 90 | 0.380 |
Why?
| | Autoimmunity | 3 | 2013 | 860 | 0.380 |
Why?
| | Clinical Protocols | 1 | 2013 | 253 | 0.370 |
Why?
| | Autoimmune Diseases | 2 | 2013 | 423 | 0.370 |
Why?
| | Compensation and Redress | 1 | 2011 | 7 | 0.370 |
Why?
| | National Health Programs | 1 | 2011 | 17 | 0.360 |
Why?
| | Protein Binding | 5 | 2019 | 2105 | 0.350 |
Why?
| | B-Lymphocytes | 1 | 2016 | 812 | 0.350 |
Why?
| | Phosphatidylinositols | 6 | 1995 | 57 | 0.350 |
Why?
| | Influenza Vaccines | 3 | 2013 | 532 | 0.350 |
Why?
| | Rats | 16 | 2015 | 5199 | 0.350 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2010 | 87 | 0.340 |
Why?
| | Leukemia, Basophilic, Acute | 5 | 1995 | 5 | 0.340 |
Why?
| | Hydroxyproline | 2 | 2023 | 22 | 0.340 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 224 | 0.320 |
Why?
| | Antibodies | 1 | 2011 | 392 | 0.320 |
Why?
| | Chronic Disease | 8 | 2018 | 1690 | 0.310 |
Why?
| | Thyroid Gland | 2 | 2009 | 94 | 0.310 |
Why?
| | Immune Tolerance | 1 | 2011 | 347 | 0.310 |
Why?
| | Type C Phospholipases | 5 | 1995 | 72 | 0.310 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 754 | 0.300 |
Why?
| | Thimerosal | 1 | 2007 | 5 | 0.290 |
Why?
| | Eosinophils | 2 | 2021 | 323 | 0.290 |
Why?
| | Phagocyte Bactericidal Dysfunction | 4 | 1987 | 12 | 0.270 |
Why?
| | Job Syndrome | 4 | 1987 | 6 | 0.270 |
Why?
| | Bone Marrow Cells | 2 | 2016 | 293 | 0.270 |
Why?
| | Disease Models, Animal | 7 | 2018 | 3936 | 0.260 |
Why?
| | HLA-D Antigens | 1 | 2006 | 34 | 0.260 |
Why?
| | Receptors, Fc | 4 | 1991 | 52 | 0.260 |
Why?
| | Leukotrienes | 1 | 2006 | 34 | 0.260 |
Why?
| | RNA, Messenger | 4 | 2007 | 2669 | 0.250 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 64 | 0.250 |
Why?
| | Epitope Mapping | 2 | 2016 | 57 | 0.250 |
Why?
| | Angioedema | 2 | 2010 | 16 | 0.240 |
Why?
| | Hypersensitivity | 3 | 2008 | 249 | 0.240 |
Why?
| | Cell Line | 8 | 2019 | 2736 | 0.240 |
Why?
| | Vaccination | 2 | 2011 | 1343 | 0.240 |
Why?
| | Isoenzymes | 2 | 2003 | 302 | 0.240 |
Why?
| | Transcriptional Activation | 1 | 2007 | 355 | 0.230 |
Why?
| | Adenosine Triphosphate | 4 | 1995 | 469 | 0.230 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2820 | 0.230 |
Why?
| | Interferon-gamma | 1 | 2008 | 760 | 0.230 |
Why?
| | Tumor Cells, Cultured | 8 | 2003 | 930 | 0.230 |
Why?
| | Down-Regulation | 2 | 2006 | 630 | 0.230 |
Why?
| | Biomarkers | 3 | 2024 | 3874 | 0.230 |
Why?
| | Immunologic Tests | 1 | 2024 | 16 | 0.220 |
Why?
| | Skin Tests | 4 | 2013 | 100 | 0.220 |
Why?
| | Cell Nucleus | 1 | 2007 | 579 | 0.220 |
Why?
| | Hospitalization | 1 | 2013 | 2057 | 0.210 |
Why?
| | Anacardium | 1 | 2023 | 1 | 0.210 |
Why?
| | Pistacia | 1 | 2023 | 2 | 0.210 |
Why?
| | Juglans | 1 | 2023 | 6 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2059 | 0.210 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2003 | 80 | 0.210 |
Why?
| | NF-kappa B | 1 | 2007 | 649 | 0.200 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1689 | 0.200 |
Why?
| | Alanine | 1 | 2023 | 141 | 0.200 |
Why?
| | Hypergammaglobulinemia | 3 | 1987 | 9 | 0.200 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2006 | 38 | 0.200 |
Why?
| | Bone Marrow | 3 | 2021 | 267 | 0.200 |
Why?
| | Mice | 9 | 2022 | 16574 | 0.190 |
Why?
| | Nasal Mucosa | 1 | 2002 | 107 | 0.190 |
Why?
| | Child, Preschool | 8 | 2019 | 10378 | 0.190 |
Why?
| | Basophil Degranulation Test | 3 | 2012 | 6 | 0.190 |
Why?
| | Female | 23 | 2019 | 68016 | 0.180 |
Why?
| | Detergents | 1 | 2001 | 45 | 0.180 |
Why?
| | Common Variable Immunodeficiency | 1 | 2001 | 27 | 0.180 |
Why?
| | Cytological Techniques | 1 | 2001 | 26 | 0.180 |
Why?
| | Histamine | 3 | 2012 | 65 | 0.180 |
Why?
| | Sesamum | 1 | 2020 | 6 | 0.180 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 3 | 1991 | 37 | 0.180 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2001 | 71 | 0.180 |
Why?
| | Middle Aged | 14 | 2015 | 30812 | 0.180 |
Why?
| | Ethnopharmacology | 1 | 2000 | 1 | 0.170 |
Why?
| | Antibodies, Monoclonal | 2 | 2019 | 1354 | 0.170 |
Why?
| | Drugs, Chinese Herbal | 1 | 2000 | 14 | 0.170 |
Why?
| | Cell Membrane | 5 | 1995 | 725 | 0.170 |
Why?
| | Pneumonia | 1 | 2006 | 600 | 0.170 |
Why?
| | Adult | 16 | 2015 | 35176 | 0.170 |
Why?
| | Antigens | 3 | 1996 | 353 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2007 | 1185 | 0.170 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 108 | 0.170 |
Why?
| | Phosphoenolpyruvate | 3 | 1995 | 3 | 0.170 |
Why?
| | Immunoblotting | 2 | 2011 | 301 | 0.160 |
Why?
| | Enzyme Activation | 6 | 2001 | 796 | 0.160 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 107 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2001 | 311 | 0.160 |
Why?
| | Nonprescription Drugs | 1 | 2000 | 66 | 0.160 |
Why?
| | Monocytes | 2 | 2007 | 546 | 0.160 |
Why?
| | Inflammation | 3 | 2007 | 2646 | 0.160 |
Why?
| | Dyspnea | 1 | 2001 | 238 | 0.160 |
Why?
| | Adhesins, Escherichia coli | 1 | 1999 | 1 | 0.160 |
Why?
| | Mycoses | 1 | 2000 | 70 | 0.160 |
Why?
| | Fimbriae Proteins | 1 | 1999 | 15 | 0.160 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 182 | 0.160 |
Why?
| | Adhesins, Bacterial | 1 | 1999 | 40 | 0.150 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 97 | 0.150 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2009 | 136 | 0.140 |
Why?
| | Awards and Prizes | 1 | 2018 | 60 | 0.140 |
Why?
| | History, 21st Century | 1 | 2018 | 177 | 0.140 |
Why?
| | Phosphocreatine | 2 | 1995 | 40 | 0.140 |
Why?
| | Binding Sites | 2 | 2016 | 1241 | 0.140 |
Why?
| | Sinusitis | 1 | 2000 | 202 | 0.140 |
Why?
| | Administration, Oral | 1 | 2019 | 766 | 0.140 |
Why?
| | History, 20th Century | 1 | 2018 | 285 | 0.140 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 37 | 0.140 |
Why?
| | Molecular Mimicry | 1 | 2017 | 37 | 0.140 |
Why?
| | Calcimycin | 1 | 1996 | 48 | 0.130 |
Why?
| | Skin | 1 | 2021 | 711 | 0.130 |
Why?
| | Male | 14 | 2019 | 62757 | 0.130 |
Why?
| | Consensus Sequence | 1 | 2016 | 72 | 0.130 |
Why?
| | Adolescent | 9 | 2019 | 20158 | 0.130 |
Why?
| | Cell Surface Display Techniques | 1 | 2016 | 11 | 0.130 |
Why?
| | Arachidonic Acid | 1 | 1996 | 114 | 0.130 |
Why?
| | Leukocyte Common Antigens | 1 | 2016 | 81 | 0.130 |
Why?
| | Magnesium | 2 | 1993 | 150 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2016 | 309 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 117 | 0.120 |
Why?
| | Child | 10 | 2015 | 20636 | 0.120 |
Why?
| | B-Lymphocyte Subsets | 1 | 2016 | 74 | 0.120 |
Why?
| | Adoptive Transfer | 1 | 2016 | 215 | 0.120 |
Why?
| | Bacteriophages | 1 | 2017 | 92 | 0.120 |
Why?
| | Cytokines | 5 | 2018 | 1984 | 0.120 |
Why?
| | Protein Array Analysis | 1 | 2015 | 56 | 0.120 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1227 | 0.120 |
Why?
| | Lung Diseases | 1 | 2001 | 713 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 146 | 0.120 |
Why?
| | Chromatography, Liquid | 2 | 2023 | 377 | 0.120 |
Why?
| | Prostaglandin D2 | 3 | 2006 | 20 | 0.110 |
Why?
| | Tryptases | 2 | 2012 | 12 | 0.110 |
Why?
| | Antigens, Dermatophagoides | 1 | 2014 | 10 | 0.110 |
Why?
| | gamma-Tocopherol | 1 | 2014 | 7 | 0.110 |
Why?
| | Lung Transplantation | 1 | 1997 | 278 | 0.110 |
Why?
| | Cyclooxygenase 2 | 2 | 2006 | 172 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 251 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 2 | 2023 | 452 | 0.110 |
Why?
| | Vitamin E | 1 | 2014 | 119 | 0.110 |
Why?
| | Genes, fos | 1 | 1993 | 33 | 0.110 |
Why?
| | Cats | 2 | 2004 | 209 | 0.110 |
Why?
| | Macrophages | 1 | 2001 | 1460 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 477 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 624 | 0.100 |
Why?
| | Headache | 1 | 2014 | 137 | 0.100 |
Why?
| | Asthma | 1 | 2006 | 2212 | 0.100 |
Why?
| | Pichia | 1 | 2012 | 22 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2008 | 1408 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 328 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 940 | 0.100 |
Why?
| | Albumins | 2 | 2023 | 101 | 0.100 |
Why?
| | Mutant Proteins | 1 | 2012 | 99 | 0.100 |
Why?
| | Transfection | 2 | 2007 | 891 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2010 | 2261 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 755 | 0.090 |
Why?
| | Complex Mixtures | 1 | 2011 | 11 | 0.090 |
Why?
| | Proteomics | 1 | 2018 | 1008 | 0.090 |
Why?
| | Blotting, Western | 2 | 2007 | 1169 | 0.090 |
Why?
| | Histamine Release | 3 | 2013 | 20 | 0.090 |
Why?
| | Lipopolysaccharides | 2 | 2007 | 854 | 0.090 |
Why?
| | Algorithms | 2 | 2008 | 1609 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2018 | 3324 | 0.090 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2006 | 46 | 0.090 |
Why?
| | Pharmacists | 1 | 2013 | 246 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 73 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2007 | 815 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 108 | 0.080 |
Why?
| | Antibody Formation | 1 | 2011 | 288 | 0.080 |
Why?
| | Medical Records | 1 | 2010 | 170 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 215 | 0.080 |
Why?
| | Autoantibodies | 2 | 2009 | 1461 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 372 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1943 | 0.080 |
Why?
| | Chromatography, Gel | 1 | 2009 | 127 | 0.080 |
Why?
| | Aged | 4 | 2015 | 21892 | 0.080 |
Why?
| | Gene Frequency | 1 | 2010 | 504 | 0.080 |
Why?
| | Ovalbumin | 2 | 2006 | 176 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 997 | 0.080 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2010 | 360 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 331 | 0.080 |
Why?
| | Haplotypes | 1 | 2010 | 471 | 0.080 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2009 | 70 | 0.080 |
Why?
| | Cytoplasm | 1 | 1989 | 257 | 0.080 |
Why?
| | Diphenhydramine | 1 | 2008 | 31 | 0.080 |
Why?
| | Infant | 5 | 2013 | 8912 | 0.080 |
Why?
| | Young Adult | 3 | 2015 | 12281 | 0.070 |
Why?
| | Histamine H1 Antagonists | 1 | 2008 | 29 | 0.070 |
Why?
| | Escherichia coli | 1 | 2012 | 766 | 0.070 |
Why?
| | Th2 Cells | 2 | 2006 | 167 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3039 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 82 | 0.070 |
Why?
| | Epinephrine | 1 | 2008 | 140 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2005 | 1105 | 0.070 |
Why?
| | Immunotherapy | 2 | 2009 | 586 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 212 | 0.070 |
Why?
| | Abscess | 1 | 1987 | 73 | 0.070 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 21 | 0.070 |
Why?
| | United States | 4 | 2018 | 13785 | 0.070 |
Why?
| | HMGB1 Protein | 1 | 2007 | 48 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2007 | 67 | 0.070 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 67 | 0.070 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 83 | 0.070 |
Why?
| | Lysine | 2 | 2001 | 282 | 0.070 |
Why?
| | Immunoprecipitation | 1 | 2007 | 157 | 0.070 |
Why?
| | Transcription Factor RelA | 1 | 2007 | 79 | 0.070 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 10 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2006 | 26 | 0.070 |
Why?
| | Nigella sativa | 1 | 2006 | 1 | 0.070 |
Why?
| | Endotoxins | 1 | 2007 | 215 | 0.060 |
Why?
| | Goblet Cells | 1 | 2006 | 18 | 0.060 |
Why?
| | Pyrophosphatases | 1 | 2006 | 21 | 0.060 |
Why?
| | Dermatitis, Atopic | 1 | 2009 | 319 | 0.060 |
Why?
| | Serum | 1 | 2006 | 57 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2005 | 15 | 0.060 |
Why?
| | Plasmids | 1 | 2007 | 354 | 0.060 |
Why?
| | Alopecia Areata | 1 | 2005 | 9 | 0.060 |
Why?
| | Environmental Exposure | 2 | 2009 | 458 | 0.060 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 104 | 0.060 |
Why?
| | Immunochemistry | 1 | 2005 | 13 | 0.060 |
Why?
| | Staphylococcal Infections | 2 | 1987 | 386 | 0.060 |
Why?
| | Vitiligo | 1 | 2005 | 41 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1264 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2005 | 54 | 0.060 |
Why?
| | Haptens | 2 | 1996 | 20 | 0.060 |
Why?
| | Leukocyte Count | 1 | 2006 | 325 | 0.060 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3168 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 961 | 0.060 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 179 | 0.060 |
Why?
| | Biological Assay | 1 | 2005 | 118 | 0.060 |
Why?
| | Staphylococcus aureus | 2 | 1987 | 434 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2001 | 430 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 858 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 1985 | 136 | 0.060 |
Why?
| | Sequence Alignment | 2 | 2014 | 329 | 0.050 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2003 | 21 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 1985 | 200 | 0.050 |
Why?
| | Vaccines | 1 | 2008 | 394 | 0.050 |
Why?
| | Nut Hypersensitivity | 1 | 2023 | 4 | 0.050 |
Why?
| | Immunologic Techniques | 1 | 2003 | 38 | 0.050 |
Why?
| | Lung | 2 | 2006 | 3745 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 822 | 0.050 |
Why?
| | Antibody Specificity | 2 | 2003 | 182 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 809 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2703 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1198 | 0.050 |
Why?
| | Cell Count | 2 | 2021 | 310 | 0.050 |
Why?
| | Signal Transduction | 4 | 2007 | 4812 | 0.050 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2021 | 10 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2001 | 4 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 2001 | 3 | 0.050 |
Why?
| | Octoxynol | 1 | 2001 | 13 | 0.050 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2001 | 12 | 0.050 |
Why?
| | Mastocytosis | 1 | 2021 | 11 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2001 | 15 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3009 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2001 | 93 | 0.050 |
Why?
| | Time Factors | 2 | 2011 | 6479 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2014 | 10110 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 9 | 1 | 2001 | 18 | 0.050 |
Why?
| | Immune Sera | 1 | 2001 | 86 | 0.050 |
Why?
| | Biopsy | 2 | 2021 | 1077 | 0.050 |
Why?
| | Enzyme Stability | 1 | 2001 | 67 | 0.050 |
Why?
| | Valine | 1 | 2001 | 80 | 0.040 |
Why?
| | Hydrolysis | 2 | 1993 | 184 | 0.040 |
Why?
| | Exocytosis | 2 | 1993 | 87 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 160 | 0.040 |
Why?
| | Bacterial Infections | 1 | 1983 | 232 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1921 | 0.040 |
Why?
| | Serine | 1 | 2001 | 135 | 0.040 |
Why?
| | Shock, Septic | 1 | 1983 | 207 | 0.040 |
Why?
| | Leukemia | 1 | 1983 | 228 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2007 | 1403 | 0.040 |
Why?
| | Medicine, Traditional | 1 | 2000 | 22 | 0.040 |
Why?
| | Gastritis | 1 | 2021 | 96 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2001 | 358 | 0.040 |
Why?
| | Radioallergosorbent Test | 1 | 2000 | 3 | 0.040 |
Why?
| | Environmental Illness | 1 | 2000 | 2 | 0.040 |
Why?
| | Catalysis | 1 | 2001 | 305 | 0.040 |
Why?
| | Enteritis | 1 | 2021 | 93 | 0.040 |
Why?
| | Hypersensitivity, Delayed | 1 | 2000 | 28 | 0.040 |
Why?
| | Protein Domains | 1 | 2021 | 252 | 0.040 |
Why?
| | Growth Hormone | 1 | 1980 | 96 | 0.040 |
Why?
| | Interleukin-3 | 2 | 1989 | 24 | 0.040 |
Why?
| | Calcium | 3 | 1991 | 1182 | 0.040 |
Why?
| | Mannose | 1 | 1999 | 25 | 0.040 |
Why?
| | Eosinophilia | 1 | 2021 | 204 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2541 | 0.040 |
Why?
| | Muscles | 1 | 1980 | 322 | 0.040 |
Why?
| | Serotonin | 1 | 2001 | 317 | 0.040 |
Why?
| | Ribosomes | 1 | 1980 | 164 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 273 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1813 | 0.040 |
Why?
| | Drug Prescriptions | 1 | 2000 | 245 | 0.040 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 318 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 1996 | 11 | 0.030 |
Why?
| | Phosphorylation | 1 | 2001 | 1681 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5353 | 0.030 |
Why?
| | Antibody Affinity | 1 | 1996 | 59 | 0.030 |
Why?
| | Latex | 1 | 1996 | 9 | 0.030 |
Why?
| | Rubber | 1 | 1996 | 6 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2001 | 598 | 0.030 |
Why?
| | Double-Blind Method | 3 | 2006 | 1852 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 495 | 0.030 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 10 | 0.030 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1995 | 14 | 0.030 |
Why?
| | Cell Fractionation | 2 | 1989 | 56 | 0.030 |
Why?
| | Vanadates | 1 | 1995 | 14 | 0.030 |
Why?
| | Oligonucleotides | 1 | 1996 | 138 | 0.030 |
Why?
| | Drug Interactions | 1 | 1996 | 361 | 0.030 |
Why?
| | Hydroxylation | 1 | 2014 | 32 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 1995 | 80 | 0.030 |
Why?
| | Leukotriene D4 | 1 | 2014 | 1 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2004 | 81 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1286 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 1993 | 5 | 0.030 |
Why?
| | Receptor Aggregation | 1 | 1993 | 10 | 0.030 |
Why?
| | Phosphotyrosine | 1 | 1993 | 36 | 0.030 |
Why?
| | Adenosine | 1 | 1995 | 212 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2001 | 1896 | 0.030 |
Why?
| | Mass Vaccination | 1 | 2013 | 16 | 0.030 |
Why?
| | Tyrosine | 1 | 1993 | 218 | 0.030 |
Why?
| | Permeability | 1 | 1993 | 156 | 0.020 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2013 | 73 | 0.020 |
Why?
| | Leukocytes | 1 | 1974 | 303 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 2 | 2004 | 65 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2012 | 148 | 0.020 |
Why?
| | Protein Kinase C | 1 | 1993 | 255 | 0.020 |
Why?
| | Air Pollutants | 1 | 1996 | 310 | 0.020 |
Why?
| | Clone Cells | 1 | 2012 | 255 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1047 | 0.020 |
Why?
| | Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1991 | 4 | 0.020 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 1991 | 5 | 0.020 |
Why?
| | Point Mutation | 1 | 2012 | 221 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1991 | 80 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1617 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1993 | 328 | 0.020 |
Why?
| | DNA | 2 | 1996 | 1392 | 0.020 |
Why?
| | Protein Folding | 1 | 2012 | 266 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1991 | 419 | 0.020 |
Why?
| | Pruritus | 1 | 2010 | 58 | 0.020 |
Why?
| | Pemphigus | 1 | 2009 | 8 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 1989 | 11 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1140 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1995 | 831 | 0.020 |
Why?
| | Psoriasis | 1 | 2009 | 85 | 0.020 |
Why?
| | Extracellular Space | 1 | 1989 | 119 | 0.020 |
Why?
| | Thyroxine | 1 | 2009 | 62 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2009 | 156 | 0.020 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 1988 | 40 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2008 | 125 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1942 | 0.020 |
Why?
| | Body Fluid Compartments | 1 | 1987 | 6 | 0.020 |
Why?
| | Influenza, Human | 1 | 2013 | 600 | 0.020 |
Why?
| | Ribonucleases | 2 | 1980 | 54 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 714 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 1987 | 108 | 0.020 |
Why?
| | Dermatitis, Contact | 1 | 1987 | 17 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2010 | 860 | 0.020 |
Why?
| | Rhinometry, Acoustic | 1 | 2006 | 1 | 0.020 |
Why?
| | IgG Deficiency | 1 | 2006 | 7 | 0.020 |
Why?
| | Psychometrics | 1 | 2010 | 679 | 0.020 |
Why?
| | Necrosis | 1 | 2007 | 228 | 0.020 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 50 | 0.020 |
Why?
| | Cells, Cultured | 3 | 2007 | 4006 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2007 | 258 | 0.020 |
Why?
| | Dinoprostone | 1 | 2006 | 187 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1997 | 2456 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 116 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1012 | 0.020 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1985 | 8 | 0.010 |
Why?
| | Immunoglobulin D | 1 | 1985 | 29 | 0.010 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1985 | 53 | 0.010 |
Why?
| | Haemophilus Infections | 1 | 1985 | 39 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2006 | 507 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 801 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1985 | 272 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2007 | 712 | 0.010 |
Why?
| | Agranulocytosis | 1 | 1983 | 30 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2598 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1999 | 3625 | 0.010 |
Why?
| | Peritonitis | 1 | 1983 | 81 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 5688 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2004 | 443 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7029 | 0.010 |
Why?
| | Hypophysectomy | 1 | 1980 | 15 | 0.010 |
Why?
| | Puromycin | 1 | 1980 | 10 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 1 | 1980 | 39 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1980 | 13 | 0.010 |
Why?
| | Thy-1 Antigens | 1 | 1999 | 10 | 0.010 |
Why?
| | Concanavalin A | 1 | 1999 | 75 | 0.010 |
Why?
| | Leucine | 1 | 1980 | 108 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1999 | 48 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4853 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 58 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1999 | 251 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2508 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2003 | 1043 | 0.010 |
Why?
| | Serotonin Antagonists | 1 | 1996 | 31 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 204 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1999 | 699 | 0.010 |
Why?
| | Photomicrography | 1 | 1974 | 7 | 0.010 |
Why?
| | Ligands | 1 | 1996 | 616 | 0.010 |
Why?
| | Aspergillus | 1 | 1974 | 15 | 0.010 |
Why?
| | Nucleic Acid Denaturation | 1 | 1974 | 32 | 0.010 |
Why?
| | Methods | 1 | 1974 | 64 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1974 | 23 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1974 | 52 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1974 | 82 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1974 | 58 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1974 | 170 | 0.010 |
Why?
| | Freezing | 1 | 1974 | 86 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1974 | 137 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1996 | 706 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1974 | 114 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2134 | 0.010 |
Why?
| | Pancreas | 1 | 1974 | 304 | 0.010 |
Why?
| | Hot Temperature | 1 | 1974 | 359 | 0.010 |
Why?
| | Chromatin | 1 | 1974 | 477 | 0.010 |
Why?
| | RNA | 1 | 1996 | 881 | 0.010 |
Why?
| | Interphase | 1 | 1989 | 31 | 0.010 |
Why?
| | Ethanol | 1 | 1974 | 585 | 0.000 |
Why?
| | Peptide Hydrolases | 1 | 1989 | 106 | 0.000 |
Why?
| | Cell Division | 1 | 1989 | 777 | 0.000 |
Why?
| | Extracellular Matrix | 1 | 1989 | 495 | 0.000 |
Why?
|
|
Dreskin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|